Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer.
Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies (mAb) and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
Lead Clinical Candidate
CONV01-α is a proprietary, first-in-class actinium-linked mAb that brings together the key advantage of a PSMA-targeted antibody (J591 / rosopatamab / CONV01) with the powerful actinium isotope.
Actinium-225 (225Ac) represents a new generation of radiotherapeutics with the ability to maximize antitumor impact while minimizing radiation exposure to adjacent normal tissue due to its more focused and precise range. 225Ac releases alpha particles that cause DNA double strand breaks within tumor cells.
Once bound to PSMA, CONV01-α is rapidly internalized, thereby delivering its radioactive payload directly into prostate cancer cells, causing irreparable DNA damage and killing the cell.
Convergent has optimized a combinatorial approach with the first proof-of-concept in radiopharmaceuticals
mAbs and ligands can be developed to bind at different sites on cell surface antigens, such as PSMA, thus not sterically hindering each other’s binding.
The mAb and ligand can be linked to different, complementary payloads (e.g., different radionuclides).
When combined with a radioligand linked to a beta emitter such as Lutetium-177 (177Lu), radio-antibody CONV01-α enhances the efficacy of the radioligand without compromising safety.
Phase I Study of CONV01-α for Metastatic Prostate Cancer
In ongoing clinical trials, CONV01-α has shown clinical activity in patients with advanced prostate cancer. In a Phase 1 Single Ascending Dose trial of CONV01-α in men with metastatic castration-resistant prostate cancer (mCRPC), most patients responded and 44% of the patients experienced a greater than 50% decline in prostate-specific antigen (PSA) levels after receiving only a single dose of CONV01-α. The patients enrolled were heavily pre-treated with prior androgen deprivation therapy, at least one androgen receptor signaling inhibitor, taxane chemotherapy, and almost half of the patients received prior 177Lu-PSMA-RL and/or 223Radium. PSMA PET positivity was not used to pre-select patients.